MTOR and head and neck carcinoma: Other treatment strategies (Table 1) are currently being pursued, such as dual inhibition of the phosphatidylinositol-3-kinase/mammalian target of rapamycin (P13K/mTOR) pathway or the use of a pan-PI3K inhibitor in association with paclitaxel in NOTCH1-mutant meta- static head and neck carcinoma [63].